Voyager Therapeutics Long Term Debt

Voyager Therapeutics (VYGR) currently reports a long-term debt of $27M as of March 2026. That compares with $35M in the prior-year period — down 21.3% year over year. Use the charts on this page to explore Voyager Therapeutics's long-term debt history and peer comparisons.

Voyager Therapeutics's long-term debt decreased from $35M to $27M — a 21.3% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Voyager Therapeutics reported $27M in long-term debt as of March 2026. That compares with $35M in the prior-year period — down 21.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $27M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Voyager Therapeutics, and consider following VYGR for alerts when major investors trade the stock.

Voyager Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $27M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VYGR with unrelated industries.